Literature DB >> 844203

Evaluation of fluorimetrically estimated serum bile acid in liver disease.

T Osuga, K Mitamura, F Mashige, D Imai.   

Abstract

Fasting serum bile acid (SBA) was measured by the enzymic fluorimetric method coupled with the NAD-resazurin system in 23 controls, 35 asymptomatic carriers of HIs antigen including 4 e antigen carriers and 91 patients with various liver diseases. All GHBs and e antigen carriers showed SBA within the normal range. SBA was most significantly correlated with serum bilirubin (gamma=0.74) and was a more sensitive index for impaired liver function than bilirubin or alkaline phosphatase in 164 radomly chosen samples from the liver disease group. In serial determinations of SBA with reference to GOT, GPT, changing patterns of these two parameters were classified into the parallel type and the discrepant type. Thirty two out of 40 cases with chronic liver disease belonged to the parallel type. SBA remained abnormal even after the normalization of transaminase in 12 out of 20 resolving episodes in cases of the parallel type, regardless of diagnosis. Since SBA changes according to the stage of the disease activity, serial and simultaneous estimation of SBA and GOT, GPT was found to be helpful in the observation of liver diseases. Maximum values of SBA elevation in an endogenous bile acid tolerance test after eating two egg yolks were higher than controls in 4 out of 7 cases with liver disease, who were associated with normal fasting SBA.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 844203     DOI: 10.1016/0009-8981(77)90502-2

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  15 in total

1.  Diagnostic value of serum bile acids and routine liver function tests in hepatobiliary diseases. Sensitivity, specificity, and predictive value.

Authors:  R Ferraris; G Colombatti; M T Fiorentini; R Carosso; W Arossa; M De La Pierre
Journal:  Dig Dis Sci       Date:  1983-02       Impact factor: 3.199

2.  Familial and nonfamilial benign recurrent cholestiasis distinguished by plasma disappearance of indocyanine green but not cholylglycine.

Authors:  G P van Berge-Henegouwen; D R Ferguson; A F Hofmann; A G De Pagter
Journal:  Gut       Date:  1978-05       Impact factor: 23.059

3.  Radioimmunoassay of serum glycocholic acid, standard laboratory tests of liver function and liver biopsy findings: comparative study of children with liver disease.

Authors:  A Matsui; H T Psacharopoulos; A P Mowat; B Portmann; G M Murphy
Journal:  J Clin Pathol       Date:  1982-09       Impact factor: 3.411

4.  Endogenous bile acid tolerance test for liver function.

Authors:  M van Blankenstein; M Frenkel; J W van den Berg; F J ten Kate; E P Bosman-Jacobs; A C Touw-Blommesteyn
Journal:  Dig Dis Sci       Date:  1983-02       Impact factor: 3.199

5.  Serum bile acids and oral ursodeoxycholic acid tolerance test in the diagnosis of esophageal varices.

Authors:  M Kadohara; H Kawasaki; C Hirayama
Journal:  Gastroenterol Jpn       Date:  1987-10

6.  The role of conjugation reactions in enhancing biliary secretion of bile acids.

Authors:  D A Vessey; J Whitney; J L Gollan
Journal:  Biochem J       Date:  1983-09-15       Impact factor: 3.857

7.  Dietary fat selectively alters transport properties of rat jejunum.

Authors:  A B Thomson; M Keelan; M T Clandinin; K Walker
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

8.  Bile acid clearance in liver disease.

Authors:  L K Luey; K W Heaton
Journal:  Gut       Date:  1979-12       Impact factor: 23.059

9.  Diagnostic value of serum immunoreactive conjugated cholic or chenodeoxycholic acids in detecting hepatobiliary diseases. Comparison with levels of 3 alpha-hydroxy bile acids determined enzymatically and with routine liver tests.

Authors:  R Ferraris; M T Fiorentini; G Galatola; P Rolfo; M De la Pierre
Journal:  Dig Dis Sci       Date:  1987-08       Impact factor: 3.199

10.  Mechanism of deoxycholic acid stimulation of the rabbit colon.

Authors:  S J Shiff; R D Soloway; W J Snape
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.